MZE829
Phase 2Small molecule
MZE829 is one of 38 small molecule programs targeting Kidney Disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
245 competitors in Kidney Disease
#DrugCompanyPhaseTrials
1Edarbi
TakedaPhase 3
Zemplar
AbbViePhase 3
Evrenzo
AstellasPhase 3
Invirase
RochePhase 3
Victoza
Novo NordiskPhase 3
Reata
BiogenPhase 3
Rituxan
RochePhase 3
Myfortic
NovartisPhase 3
Aranesp
AmgenPhase 3
Gazyva
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MZE829. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMaze Therapeutics